Cure Pharmaceutical Holding Corp - ESG Rating & Company Profile powered by AI
The Sustainability rating for Cure Pharmaceutical Holding Corp indicates its transparency towards the United Nations SDGs. Scroll down to the bottom of this page for potential risks for Cure Pharmaceutical Holding Corp based on sector, geography and marketcap. If you work at Cure Pharmaceutical Holding Corp and you wish to use your ESG rating, please contact us.
Cure Pharmaceutical Holding Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 0.0, social score of 5.3 and governance score of 5.3.
3.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1144 | Veerhealth Care Ltd | 3.6 | Medium |
1144 | iStreet Network Ltd | 3.6 | Medium |
1186 | Cure Pharmaceutical Holding Corp | 3.5 | Medium |
1186 | CRISPR Therapeutics AG | 3.5 | Medium |
1186 | Catalent Inc | 3.5 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Cure Pharmaceutical Holding Corp have an accelerator or VC vehicle to help deliver innovation?
Does Cure Pharmaceutical Holding Corp disclose current and historical energy intensity?
Does Cure Pharmaceutical Holding Corp report the average age of the workforce?
Does Cure Pharmaceutical Holding Corp reference operational or capital allocation in relation to climate change?
Does Cure Pharmaceutical Holding Corp disclose its ethnicity pay gap?
Does Cure Pharmaceutical Holding Corp disclose cybersecurity risks?
Does Cure Pharmaceutical Holding Corp offer flexible work?
Does Cure Pharmaceutical Holding Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Cure Pharmaceutical Holding Corp disclose the number of employees in R&D functions?
Does Cure Pharmaceutical Holding Corp conduct supply chain audits?
Does Cure Pharmaceutical Holding Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Cure Pharmaceutical Holding Corp conduct 360 degree staff reviews?
Does Cure Pharmaceutical Holding Corp disclose the individual responsible for D&I?
Does Cure Pharmaceutical Holding Corp disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Cure Pharmaceutical Holding Corp disclose current and / or historical scope 2 emissions?
Does Cure Pharmaceutical Holding Corp disclose water use targets?
Does Cure Pharmaceutical Holding Corp have careers partnerships with academic institutions?
Did Cure Pharmaceutical Holding Corp have a product recall in the last two years?
Does Cure Pharmaceutical Holding Corp disclose incidents of discrimination?
Does Cure Pharmaceutical Holding Corp allow for Work Councils/Collective Agreements to be formed?
Has Cure Pharmaceutical Holding Corp issued a profit warning in the past 24 months?
Does Cure Pharmaceutical Holding Corp disclose parental leave metrics?
Does Cure Pharmaceutical Holding Corp disclose climate scenario or pathway analysis?
Does Cure Pharmaceutical Holding Corp disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Cure Pharmaceutical Holding Corp disclose the pay ratio of women to men?
Does Cure Pharmaceutical Holding Corp support suppliers with sustainability related research and development?
Does Cure Pharmaceutical Holding Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Cure Pharmaceutical Holding Corp reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Cure Pharmaceutical Holding Corp involved in embryonic stem cell research?
Does Cure Pharmaceutical Holding Corp disclose GHG and Air Emissions intensity?
Does Cure Pharmaceutical Holding Corp disclose its waste policy?
Does Cure Pharmaceutical Holding Corp report according to TCFD requirements?
Does Cure Pharmaceutical Holding Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Cure Pharmaceutical Holding Corp disclose energy use targets?
Does Cure Pharmaceutical Holding Corp disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Cure Pharmaceutical Holding Corp have a policy relating to cyber security?
Have a different question?
Potential Risks for Cure Pharmaceutical Holding Corp
These potential risks are based on the size, segment and geographies of the company.
CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It also sells various wellness products under its distribution partners' brands. In addition, the company develops 50,000IU and Vitamin D3 OTF for oral administration. It has a licensing agreement with Canopy Growth Corporation. The company was founded in 2011 and is headquartered in Oxnard, California.